Notice of NHLBI Participation in PAR-21-252 "Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)"
Notice Number:
NOT-HL-22-037

Key Dates

Release Date:

July 25, 2022

Related Announcements

PAR-21-252 - Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform potential applicants that the National Heart, Lung, and Blood Institute (NHLBI) is participating, effective immediately, in PAR-21-252 "Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)".

The following sections of PAR-21-252 have been updated (in bold italics) to reflect NHLBI participation in this Funding Opportunity Announcement.

Part 1. Overview Information

Components of Participating Organizations

Fogarty International Center (FIC)

National Cancer Institute (NCI)

National Human Genome Research Institute (NHGRI)

National Institute on Aging (NIA)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute of Environmental Health Sciences (NIEHS)

National Institute of Mental Health (NIMH)

National Institute of Neurological Disorders and Stroke (NINDS)

National Heart, Lung, and Blood Institute (NHLBI)

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Office of Research on Women's Health (ORWH)  

Catalog of Federal Domestic Assistance (CFDA) Number(s) 93.989, 93.398, 93.172, 93.121, 93.113, 93.242, 93.853, 93.837, 93.838, 93.839, 93.840, 93.233

Part 2. Section I. Funding Opportunity Description

Interests of Participating NIH Institutes, Centers and Offices

The National Heart, Lung, and Blood Institute (NHLBI) is interested in applications that promote the prevention and treatment of heart, lung, blood, or sleep (HLBS) disorders in low- and middle-income countries (LMICs). Examples of HLBS diseases and disorders include, but are not limited to, hypertension, obesity, rheumatic heart disease, chronic obstructive lung diseases, asthma, and sickle cell disease. Training across the spectrum of research disciplines is encouraged, from basic biomedical, behavioral and social science to clinical and applied sciences, including translational and implementation science that emphasizes the resources, context and needs of multiple stakeholders in local settings. Training on research skills, research design and methodology, ethics, data management and analysis, grant writing, manuscript writing, scientific presentations and research administration should be included in the career development plan. Mentors should have strong track records in HLBS research and training early stage investigators for independent research careers. The mentored research career development experience should lead to an independently-funded research career on HLBS diseases and disorders across the lifespan and build scientific capacity for HLBS research at LMIC institutions.

Part 2. Section VII. Agency Contacts

Scientific/Research Contact(s)
Makeda Williams, Ph.D., M.P.H.
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-451-7594
Email:willimak@mail.nih.gov

Grants Management Contact(s)
Kimberly Stanton
National Heart, Lung, and Blood Institute (NHLBI)
Phone: (301) 435-0166
Email: stantonk@nhlbi.nih.gov

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries regarding this Notice to:

Makeda Williams, Ph.D., M.P.H.
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-451-7594
Email: willimak@mail.nih.gov